Association of ABO Blood Type with Infection and Severity of COVID-19 in Inpatient and Longitudinal Cohorts
Introduction: The objectives of this study were to (1) investigate the association between human blood type and COVID-19 infection in both inpatient and longitudinal populations at our institution in South Florida and (2) identify the association between blood type and severity of COVID-19 infection via presence of cellular biomarkers of severe infection in hospitalized individuals.
 
 Methods: This study consists of (1) a single-center retrospective analysis of 669 of 2,741 COVID-19 positive screened patients seen from January 1, 2020 until March 31, 2021 at the University of Miami Emergency Department (ED) who tested positive for COVID-19 infection and had a documented ABO blood type and (2) a longitudinal SARS-CoV-2 immunity study (“CITY”) at the University of Miami Miller School of Medicine consisting of 185 survey participants. COVID-19 outcome rates and 95% confidence intervals were calculated for each ABO blood type and Rh group using Chi-squared tests for categorical and ANOVA for continuous variables in the inpatient cohort and Chi-squared tests for the longitudinal cohort, all executed in R studio.
 
 Results: Our inpatient cohort had a mean age of 53.6 (± 17.9) years with 48% males and 52% females. When compared to patients with other blood types, those with O- demonstrated less risk of developing COVID-19 pneumonia (26.7% for O- vs. 69.2% for type A-, 56.5% for A+, 71.4% for AB+, 53.7% for B+, 51.5% for O+, p-value= 0.003 via Chi-squared test) and decreased mortality due to COVID-19 infection (17.0% mortality for O vs. 26.3% for A, 29.2% for B, p-value= 0.012 via Chi-squared test). Blood type O- demonstrated less elevated levels of LDH than did other blood types (p-value= 0.001, ANOVA) and a higher frequency of clinically accepted baseline levels of troponin (0.04 ng/mL) (p-value= 0.026, ANOVA) (Figure 1). 
 
 Most of the longitudinal cohort was ABO blood grouping type O (47% (87/185)), with 33.5% type A, 14.1% B, and 5.4% AB. Most individuals were Rh positive (85.9%). There was no significant association found between COVID status (infection vs. non-infection) and ABO (Chi-squared test (3, N = 185) = 1.8, p = 0.6) or Rh (Chi-squared test (1, N = 185) = 0.16, p = 0.7) blood typing. Nearly all participants had been vaccinated (95.1% (176/185)), with a majority reporting primary vaccination with Pfizer (57.8% (107/185)), followed by Moderna (33% (61/185)), and Johnson & Johnson (4.3% (8/185)). 8 participants (4.3%) were unvaccinated. 
 
 Conclusions: In an inpatient setting, blood type O sustained less risk of COVID-19 mortality and O- demonstrated less risk of developing COVID-19 pneumonia. In a longitudinal setting, there was no association found between blood type and COVID-19 severity. As the novelty of COVID-19 infection declines with time, further studies on risk-stratification by blood type are encouraged..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Preprints.org - (2023) vom: 20. Sept. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Eatz, Tiffany Alyssa [VerfasserIn] |
---|
Links: |
---|
doi: |
10.20944/preprints202308.0881.v1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
preprintsorg040507408 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | preprintsorg040507408 | ||
003 | DE-627 | ||
005 | 20231205144420.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230814s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.20944/preprints202308.0881.v1 |2 doi | |
024 | 7 | |a 10.20944/preprints202308.0881.v1 |2 doi | |
035 | |a (DE-627)preprintsorg040507408 | ||
035 | |a (preprintsorg)10.20944/preprints202308.0881 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Eatz, Tiffany Alyssa |e verfasserin |0 (orcid)0000-0003-3861-8335 |4 aut | |
245 | 1 | 0 | |a Association of ABO Blood Type with Infection and Severity of COVID-19 in Inpatient and Longitudinal Cohorts |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Introduction: The objectives of this study were to (1) investigate the association between human blood type and COVID-19 infection in both inpatient and longitudinal populations at our institution in South Florida and (2) identify the association between blood type and severity of COVID-19 infection via presence of cellular biomarkers of severe infection in hospitalized individuals.
 
 Methods: This study consists of (1) a single-center retrospective analysis of 669 of 2,741 COVID-19 positive screened patients seen from January 1, 2020 until March 31, 2021 at the University of Miami Emergency Department (ED) who tested positive for COVID-19 infection and had a documented ABO blood type and (2) a longitudinal SARS-CoV-2 immunity study (“CITY”) at the University of Miami Miller School of Medicine consisting of 185 survey participants. COVID-19 outcome rates and 95% confidence intervals were calculated for each ABO blood type and Rh group using Chi-squared tests for categorical and ANOVA for continuous variables in the inpatient cohort and Chi-squared tests for the longitudinal cohort, all executed in R studio.
 
 Results: Our inpatient cohort had a mean age of 53.6 (± 17.9) years with 48% males and 52% females. When compared to patients with other blood types, those with O- demonstrated less risk of developing COVID-19 pneumonia (26.7% for O- vs. 69.2% for type A-, 56.5% for A+, 71.4% for AB+, 53.7% for B+, 51.5% for O+, p-value= 0.003 via Chi-squared test) and decreased mortality due to COVID-19 infection (17.0% mortality for O vs. 26.3% for A, 29.2% for B, p-value= 0.012 via Chi-squared test). Blood type O- demonstrated less elevated levels of LDH than did other blood types (p-value= 0.001, ANOVA) and a higher frequency of clinically accepted baseline levels of troponin (0.04 ng/mL) (p-value= 0.026, ANOVA) (Figure 1). 
 
 Most of the longitudinal cohort was ABO blood grouping type O (47% (87/185)), with 33.5% type A, 14.1% B, and 5.4% AB. Most individuals were Rh positive (85.9%). There was no significant association found between COVID status (infection vs. non-infection) and ABO (Chi-squared test (3, N = 185) = 1.8, p = 0.6) or Rh (Chi-squared test (1, N = 185) = 0.16, p = 0.7) blood typing. Nearly all participants had been vaccinated (95.1% (176/185)), with a majority reporting primary vaccination with Pfizer (57.8% (107/185)), followed by Moderna (33% (61/185)), and Johnson & Johnson (4.3% (8/185)). 8 participants (4.3%) were unvaccinated. 
 
 Conclusions: In an inpatient setting, blood type O sustained less risk of COVID-19 mortality and O- demonstrated less risk of developing COVID-19 pneumonia. In a longitudinal setting, there was no association found between blood type and COVID-19 severity. As the novelty of COVID-19 infection declines with time, further studies on risk-stratification by blood type are encouraged. | ||
700 | 1 | |a Mantero, Alejandro Max Antonio |4 aut | |
700 | 1 | |a Williams, Erin Caitlin |4 aut | |
700 | 1 | |a Cash, Charles Joseph |4 aut | |
700 | 1 | |a Perez, Nathalie Elisabeth |4 aut | |
700 | 1 | |a Cromar, Zachary James |4 aut | |
700 | 1 | |a Hernandez, Adiel |4 aut | |
700 | 1 | |a Cordova, Matthew Moses |4 aut | |
700 | 1 | |a Godbole, Neha Pradyumna |4 aut | |
700 | 1 | |a Anh, Le Pham |4 aut | |
700 | 1 | |a Lin, Rachel Rebecca |0 (orcid)0000-0002-7810-2571 |4 aut | |
700 | 1 | |a Luo, Sherry |4 aut | |
700 | 1 | |a Patel, Anmol Bharat |4 aut | |
700 | 1 | |a Abu, Yaa Fosuah |4 aut | |
700 | 1 | |a Pallikkuth, Suresh |4 aut | |
700 | 1 | |a Pahwa, Savita G |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Preprints.org |g (2023) vom: 20. Sept. |
773 | 1 | 8 | |g year:2023 |g day:20 |g month:09 |
856 | 4 | 0 | |u https://doi.org/10.3390/covid3090098 |z lizenzpflichtig |3 Volltext |
856 | 4 | 0 | |u http://dx.doi.org/10.20944/preprints202308.0881.v1 |z kostenfrei |3 Volltext |
912 | |a preprintsorg | ||
951 | |a AR | ||
952 | |j 2023 |b 20 |c 09 |